302 related articles for article (PubMed ID: 36135837)
21. Epidemiology and prevention of human papillomavirus and cervical cancer in China and Mongolia.
Shi JF; Qiao YL; Smith JS; Dondog B; Bao YP; Dai M; Clifford GM; Franceschi S
Vaccine; 2008 Aug; 26 Suppl 12():M53-9. PubMed ID: 18945414
[TBL] [Abstract][Full Text] [Related]
22. New prophylactics human papilloma virus (HPV) vaccines against cervical cancer.
Barra F; Leone Roberti Maggiore U; Bogani G; Ditto A; Signorelli M; Martinelli F; Chiappa V; Lorusso D; Raspagliesi F; Ferrero S
J Obstet Gynaecol; 2019 Jan; 39(1):1-10. PubMed ID: 30370796
[TBL] [Abstract][Full Text] [Related]
23. HPV Update: Vaccination, Screening, and Associated Disease.
McNamara M; Batur P; Walsh JME; Johnson KM
J Gen Intern Med; 2016 Nov; 31(11):1360-1366. PubMed ID: 27184752
[TBL] [Abstract][Full Text] [Related]
24. Impact of gender-neutral or girls-only vaccination against human papillomavirus-Results of a community-randomized clinical trial (I).
Lehtinen M; Söderlund-Strand A; Vänskä S; Luostarinen T; Eriksson T; Natunen K; Apter D; Baussano I; Harjula K; Hokkanen M; Kuortti M; Palmroth J; Petäjä T; Pukkala E; Rekonen S; Siitari-Mattila M; Surcel HM; Tuomivaara L; Paavonen J; Dillner J; Dubin G; Garnett G
Int J Cancer; 2018 Mar; 142(5):949-958. PubMed ID: 29055031
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
[TBL] [Abstract][Full Text] [Related]
26. Cervical cancer and HPV vaccines in developing countries.
Karimi Zarchi M; Behtash N; Chiti Z; Kargar S
Asian Pac J Cancer Prev; 2009; 10(6):969-74. PubMed ID: 20192568
[TBL] [Abstract][Full Text] [Related]
27. High Uptake and Series Completion of COVID-19 Vaccine at Community-Based Vaccination for Latinos With Limited English Proficiency.
Bigelow BF; Saxton RE; Martínez DA; Flores-Miller A; Shin JM; Parent C; Williams S; Phillips KH; Yang C; Page KR
J Public Health Manag Pract; 2022 Nov-Dec 01; 28(6):E789-E794. PubMed ID: 36074797
[TBL] [Abstract][Full Text] [Related]
28. Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study.
Simms KT; Steinberg J; Caruana M; Smith MA; Lew JB; Soerjomataram I; Castle PE; Bray F; Canfell K
Lancet Oncol; 2019 Mar; 20(3):394-407. PubMed ID: 30795950
[TBL] [Abstract][Full Text] [Related]
29. Recommendations for cervical cancer prevention in Asia Pacific.
Garland SM; Cuzick J; Domingo EJ; Goldie SJ; Kim YT; Konno R; Parkin DM; Qiao YL; Sankaranarayanan R; Stern PL; Tay SK; Bosch FX
Vaccine; 2008 Aug; 26 Suppl 12():M89-98. PubMed ID: 18945418
[TBL] [Abstract][Full Text] [Related]
30. Impact of HPV vaccination on HPV infection and cervical related disease burden in real-world settings (HPV-RWS): protocol of a prospective cohort.
Liu Z; Li P; Zeng X; Yao X; Sun Y; Lin H; Shen P; Sun F; Zhan S
BMC Public Health; 2022 Nov; 22(1):2117. PubMed ID: 36401179
[TBL] [Abstract][Full Text] [Related]
31. Human Pappilomavirus (HPV) induced cancers and prevention by immunization.
Khaliq SA; Shyum Naqvi SB; Fatima A
Pak J Pharm Sci; 2012 Oct; 25(4):763-72. PubMed ID: 23009992
[TBL] [Abstract][Full Text] [Related]
32. [AN HPV-ASSOCIATED DISEASES AND CERVICAL CANCER AND PROPHYLACTIC HUMAN PAPILLOMAVIRUS (HPV) VACCINES].
Malinova M
Akush Ginekol (Sofiia); 2015; 54 Suppl 1():25-31. PubMed ID: 26137767
[TBL] [Abstract][Full Text] [Related]
33. High-risk HPV prevalence and vaccination coverage among Indigenous women in the Colombian Amazon: Implications for cervical cancer prevention. Cross-sectional study.
Sarmiento-Medina MI; de Amaya MP; Villamizar-Gómez L; González-Coba AC; Guzmán-Barajas L
PLoS One; 2024; 19(2):e0297579. PubMed ID: 38315664
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
[TBL] [Abstract][Full Text] [Related]
35. MOnitoring human papillomavirus Vaccine effect on Infection and cErvical diseases (MOVIE): Protocol for a cohort study using electronic health records from Yinzhou, China.
Deng S; Welby S; Liu Z; Yang Y; Meng R; Sun Y; Yang J; Liu G; He Y; Jiang N; Wu Z; Liu K; Rosillon D; Cohet C; Borys D; Zhan S
Hum Vaccin Immunother; 2023 Aug; 19(2):2257989. PubMed ID: 37813849
[TBL] [Abstract][Full Text] [Related]
36. The Vaccine and Cervical Cancer Screen (VACCS) project: Linking cervical cancer screening to HPV vaccination in the South-West District of Tshwane, Gauteng, South Africa.
Snyman LC; Dreyer G; Botha MH; van der Merwe FH; Becker PJ
S Afr Med J; 2015 Jan; 105(2):115-20. PubMed ID: 26242529
[TBL] [Abstract][Full Text] [Related]
37. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
[TBL] [Abstract][Full Text] [Related]
38. Targeting human papillomavirus to reduce the burden of cervical, vulvar and vaginal cancer and pre-invasive neoplasia: establishing the baseline for surveillance.
Nygård M; Hansen BT; Dillner J; Munk C; Oddsson K; Tryggvadottir L; Hortlund M; Liaw KL; Dasbach EJ; Kjær SK
PLoS One; 2014; 9(2):e88323. PubMed ID: 24505474
[TBL] [Abstract][Full Text] [Related]
39. Long-term impact of human papillomavirus vaccination on infection rates, cervical abnormalities, and cancer incidence.
Bogaards JA; Coupé VM; Xiridou M; Meijer CJ; Wallinga J; Berkhof J
Epidemiology; 2011 Jul; 22(4):505-15. PubMed ID: 21540743
[TBL] [Abstract][Full Text] [Related]
40. The long term vaccine-induced anti-SARS-CoV-2 immune response is impaired in quantity and quality under TNFα blockade.
Geisen UM; Rose R; Neumann F; Ciripoi M; Vullriede L; Reid HM; Berner DK; Bertoglio F; Hoff P; Hust M; Longardt AC; Lorentz T; Martini GR; Saggau C; Schirmer JH; Schubert M; Sümbül M; Tran F; Voß M; Zeuner R; Morrison PJ; Bacher P; Fickenscher H; Gerdes S; Peipp M; Schreiber S; Krumbholz A; Hoyer BF
J Med Virol; 2022 Dec; 94(12):5780-5789. PubMed ID: 35945627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
